Showing results (451-460 of 525) with videos related to

Sort By:
Pageof 53
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Scientific Reports|December 29, 2019
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vectorM Giel-Moloney, M Esteban, B H Oakes, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
The Journal of Infectious Diseases|January 12, 2018
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 TrialYouyi Fong, Xiaoying Shen, Vicki C Ashley, et al.
Nature Medicine|September 28, 2018
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individualsYotam Bar-On, Henning Gruell, Till Schoofs, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
Cell Reports|December 28, 2017
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal ModelsKevin O Saunders, Laurent K Verkoczy, Chuancang Jiang, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
Pageof 53